Skip to main content
NIH Record - National Institutes of Health

Investigational Covid-19 vaccine Well-Tolerated and Generates Immune Response in Older Adults

A phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published Sept. 29 in the New England Journal of Medicine describes the findings from the study, which was supported by NIAID.


Back to Top